Carbonic anhydrase-IN-35

Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM) . Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer[1].

Product Specifications

UNSPSC

12352100

Target

Apoptosis; Bcl-2 Family; Carbonic Anhydrase; CDK

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=S(C1=CC=C(N2N=NC(C(N/N=C/C3=CC=C(O)C=C3)=O)=C2C)C=C1)(N)=O

Molecular Formula

C17H16N6O4S

Molecular Weight

400.41

References & Citations

[1]Ibrahim MH, et al. Sulfonamide-arylidene hybrids featuring flexible hydrazide and rigid triazole linkers: design, synthesis, and evaluation as carbonic anhydrase inhibitors with anti-breast cancer potential. Bioorg Chem. 2025 Jul 29;164:108803.